Helix Reader
At the Bench

Q386 min at full depthPublished 23 Oct 2026

What Color Is Tirzepatide and What B12 Changes

The short answer

Approved Zepbound and Mounjaro solutions are clear and colorless to slightly yellow. A compounded mix with B12 looks red or pink because cyanocobalamin is red, and color is not a quality check.

The short read

  1. The Zepbound and Mounjaro labels say the liquid is clear, colorless to slightly yellow.
  2. Vitamin B12 is red, so a mix containing it is red or pink, which can hide haze or particles.
  3. Compounded tirzepatide with B12 has no FDA review, and color cannot show strength or sterility.

The approved pens and vials contain a clear liquid, colorless to slightly yellow, and the labels say not to use them if particles or discoloration appear. Compounded mixes with vitamin B12 look red or pink because cyanocobalamin is a red compound. That color does not show quality. The FDA does not review compounded drugs for safety, effectiveness or quality, and a red liquid can hide the very signs the label tells you to check.

The full explanation

What color is tirzepatide? In the approved pens and vials made by Eli Lilly, the liquid is clear and colorless to slightly yellow, and the label tells you to check it every time. Add vitamin B12 in a compounded mix and the liquid turns red or pink, because cyanocobalamin is red. Neither color tells you whether a product is safe. This article reads the Zepbound and Mounjaro labels, the cyanocobalamin label and the FDA warnings on compounded GLP 1 drugs, then explains why color is a poor quality test and what to do when an approved pen looks wrong.

What Color Is Tirzepatide in an Approved Pen

The Zepbound label describes the medicine as a clear, colorless to slightly yellow, sterile solution for subcutaneous use. The Mounjaro label uses the same words. Both labels also give an instruction for the person holding the pen: inspect the product visually before use, expect it to look clear and colorless to slightly yellow, and do not use it if particulate matter or discoloration is seen. The patient instructions repeat the check in plainer language, telling you to make sure the medicine is not frozen, is not cloudy, is colorless to slightly yellow and has no particles. So the answer to tirzepatide color for the approved product is not a single shade but a narrow range.

The word slightly matters. A faint yellow tint is inside the range the label accepts. Cloudiness, flecks or a brown or pink shift are different, because they are the signs the label tells you to act on. The label also says not to use the product if it has been frozen. These checks are cheap and take a few seconds, which is why they are written into the instructions. They only work because the expected appearance is known in advance, and that is true of a labeled, standardized product, not of an unlabeled mix whose maker never says what normal should look like. For the tirzepatide color question, the label is the only reference that has been through regulatory review.

Why B12 Turns the Liquid Red

People ask what color is tirzepatide with b12 because compounded mixes that include vitamin B12 look different from the approved pens. Cyanocobalamin, the form of B12 in many injections, appears as dark red crystals or red powder, and a label for cyanocobalamin injection describes the finished product as a red solution. It also says B12 coenzymes are very unstable in light and tells you to protect the product from light, so storage and handling matter for these mixes in a way that a plain color check cannot capture. A pink or red liquid in a compounded vial is therefore what you would expect from the vitamin, and it says nothing about the tirzepatide in the mix.

That is also the problem. A red ingredient hides exactly the signs the Zepbound label asks you to look for. Slight yellowing, haze or fine particles are much harder to see in a red liquid than in a colorless one. The FDA page on unapproved GLP 1 drugs, current as of October 1, 2026, does not mention B12 or any other additive, and compounded tirzepatide plus B12 has no FDA review as a combination. So the color of tirzepatide with b12 is a result of adding a red ingredient, not a sign of anything about quality, purity or strength, and a pale pink shade does not mean a small amount any more than a deep red means a large one.

ProductWhat the label says about the liquidSource
Zepbound pen or vialClear, colorless to slightly yellowZepbound label
Mounjaro pen or vialClear, colorless to slightly yellowMounjaro label
Cyanocobalamin injectionRed solution, protect from lightCyanocobalamin label
Compounded tirzepatide with B12No label, no FDA reviewFDA statement on compounded drugs

Why Color Is Not a Quality Check

Color shows one thing: light absorbed by something in the liquid. It does not show how much tirzepatide is present, whether the peptide is the right one, whether bacterial toxins are absent or whether the vial is sterile. The FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed. It also says it is aware of fraudulent compounded semaglutide and tirzepatide in the United States, and that such products could contain the wrong or harmful ingredients. A convincing color is easy to copy, so it cannot separate a real product from a fake, and two vials that look identical can hold very different amounts. Only testing by a laboratory, with a record tied to the batch, can speak to those things.

The FDA reports more than 730 adverse event reports associated with compounded tirzepatide. A report is not proof that the drug caused the event, but the number shows the product is in real use, with real harm reports, without the review an approved drug receives. The FDA advises that compounded drugs should only be used when a patient's medical needs cannot be met by an approved drug. It also says patients should get a prescription from their doctor and fill it at a state licensed pharmacy, and should not use an injectable GLP 1 drug that arrives warm or poorly refrigerated. For multi dose vials it also advises discarding the vial within 28 days after first use, even if medicine remains.

What to Do When an Approved Pen Looks Wrong

If an approved Zepbound or Mounjaro pen or vial looks cloudy, contains particles or looks discolored, the label says not to use it. Keep the pen and its packaging, note the lot number, and take it back to the pharmacy that supplied it. The Zepbound label lists a phone number for questions or problems with the pen, 1 800 545 5979, and the pharmacist can report the problem to the maker and to the FDA. Side effects can be reported through the FDA MedWatch program, and a report about a faulty pen helps the maker trace the batch if other people have had the same trouble.

A pen that was frozen or left in heat should also be set aside, since the label names freezing as a reason not to use the medicine. If you are unsure whether the pen was stored properly, ask the pharmacist before you inject, because a replacement costs far less than a bad injection. Keep the pen in its original carton in the refrigerator as the label directs, and note how long it spent at room temperature, since the label sets a limit for that as well. If you hold a compounded product, the same rule applies with less certainty, because there is no label to say what normal looks like. Ask the dispensing pharmacy for the written beyond use date and the ingredient list, and be wary of any answer that relies on color alone.

Conclusion

What color is tirzepatide? Clear and colorless to slightly yellow in the approved Zepbound and Mounjaro products, and red or pink when a compounded mix includes B12. Color is only a visual check against a known standard, and it says nothing about identity, strength or sterility. A compounded combination with B12 has no FDA review. If an approved pen looks cloudy, discolored or has particles, do not use it, and ask your pharmacist.

Sources

  1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  2. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  3. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1e35c97-2157-454e-967f-53a4300827de
  4. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Education only. Not medical advice, no dosing, no product recommendations. Read this first.